PVLA
Palvella Therapeutics Inc

115
Loading...
Loading...
News
all
press releases
News Placeholder
Pavella - Undiscovered Biotechnology Stock
Summary Pavella Therapeutics (PVLA) has shown significant price appreciation, gaining 90% since a Trend Seeker buy signal on 2/5, and 105.81% over the last year. The company focuses on developing therapies for rare genetic skin diseases, with its lead product QTORIN rapamycin in advanced clinical trials. Technical indicators are strong...
barchart.com·6mo ago

Latest PVLA News

View

Advertisement. Remove ads.

Advertisement. Remove ads.

Advertisement. Remove ads.